Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients

• Conditions: Diabetes
• Interventions: Procedure: Blood withdrawal

• Registration Number: NCT01781754
• Lead Sponsor: Tel-Aviv Sourasky Medical Center

Brief Summary

Many patients with Diabetes find difficulties in achieving glycemic control. Hemoglobin A1c(HgBA1c) is used as a marker for glycemic control. UCP2 is affected by high glucose levels, high free fatty acids and high oxidative stress.

The investigators intend to learn about the changes in UCP2 along the process of reaching glycemic control.

Detailed Description

Not available

Study Timeline

• Status Verified: 2013-01
• Study Start: 2013-01
• Study First Submitted: 2013-01-08
• Study First Submitted QC: 2013-01-30
• Last Update Submitted: 2013-01-30
• Study First Posted: 2013-02-01
• Last Update Posted: 2013-02-01
• Primary Completion: 2014-01
• Study Completion: 2014-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Un balanced diabetic patients.

Exclusion Criteria

• No current infection.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Diabetic patients	Blood withdrawal	Un balanced diabetic patients

Primary Outcome Measures

Name	Time	Method
Levels of gene expression for UCP2 (RQ)	6 months	Checking UCP2 levels compared to HgBA1c

Secondary Outcome Measures

Name	Time	Method
Improved metabolic state	6 months	Glycemic control (glucose level and HgA1c), levels of free reactive oxygen species (ROS) and non-esterified fatty acids (NEFAs).

Trial Locations

Locations (1)

Tel Aviv Sourasky Medical Center; 🇮🇱 Tel-Aviv, Israel